The HYDRO-RESPOND trial is a 12-week randomized controlled study investigating the effects of daily hydrogen-rich water (HRW) consumption on body composition and metabolic biomarkers in adults diagnosed with metabolic syndrome. The study also explores whether individual differences in baseline breath hydrogen levels influence response to HRW. Participants are randomly assigned to receive either HRW or a placebo, with outcomes including changes in body fat, waist circumference, glucose metabolism, lipid profiles, and inflammatory markers. The trial aims to determine the therapeutic potential of HRW and identify predictors of individual responsiveness.

Inclusion Criteria:

• Age 30-65 years

• Metabolic syndrome (NHS) (at least 3 of the 5 following criteria):

  • Waist circumference of ≥ 102 cm in men and ≥ 88 cm in women
  • Hypertriglyceridemia (≥ 1.695 mmol/L)
  • Low HDL-C (< 1.04 mmol/dL in men and < 1.30 mmol/dL in women)
  • High blood pressure (> 130/85 mmHg)
  • High fasting glucose (> 6.1 mmol/L)

• Not physically active

• Informed consent signed

Exclusion Criteria:

• Major chronic disease and acute injuries
• History of dietary supplement use during the past 4 weeks
• History of metabolism-modulating pharmaceuticals use during the past 4 weeks
• No consent to randomization
• Participation in other studies

Data obtained through this study may be provided to qualified researchers with academic interest in metabolic syndrome. Data will be coded, with no PHI included. Approval of the request and execution of all applicable agreements are prerequisites to the sharing of data with the requesting party.

Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.

Only qualified researchers with academic interest in metabolic syndrome or molecular hydrogen research